| Bioactivity | CCG-4986 is an RGS protein inhibitor. CCG-4986 inhibits protein activity by covalently modifying the Cys-132 site of RGS4. CCG-4986 can be used to study diseases related to dysregulated G protein-coupled receptor (GPCR) signaling, such as Parkinson's disease and opioid addiction[1]. |
| CAS | 7134-19-2 |
| Formula | C13H11ClN2O5S2 |
| Molar Mass | 374.82 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kimple AJ, et al. The RGS protein inhibitor CCG-4986 is a covalent modifier of the RGS4 Galpha-interaction face. Biochim Biophys Acta. 2007 Sep;1774(9):1213-20. |
CCG-4986
CAS: 7134-19-2 F: C13H11ClN2O5S2 W: 374.82
CCG-4986 is an RGS protein inhibitor. CCG-4986 inhibits protein activity by covalently modifying the Cys-132 site of RGS
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.